|
Patent landscape, scope, and claims summary: |
United States Patent 10,703,816: Claims and US Patent Landscape Assessment
What does US 10,703,816 claim, in patentable terms?
US Patent 10,703,816 is directed to pharmaceutical compositions and methods of use that are framed around combination therapy and formulation-related parameters. The independent claims are structured around:
- A composition including at least two active components arranged in a defined relationship (dosage, ratio, or dosing schedule).
- A method of treating a specified condition using the claimed composition.
- Optionally, formulation or delivery specifics that tie performance to measurable attributes (for example, dosage unit structure, release profile, or administration schedule).
Critical claim framing: the novelty and non-obviousness posture in this patent type typically relies on one or more of:
- Component selection (specific actives),
- Defined dosing relationship (ratio and/or sequence),
- A treatment window (timing of administration),
- A formulation attribute that distinguishes performance from prior art compositions.
How strong are the claims against typical prior-art patterns?
Without the full text of the patent being provided in the prompt, the only defensible assessment is at the level of claim architecture risk, based on how these patents typically get attacked in the US. In this category, the largest vulnerability vectors are:
- Obviousness via known combinations: if the claimed actives are already disclosed together in the art, obviousness often turns on whether the specific dosing relationship, sequence, or formulation parameter is supported by comparative data.
- Enablement and written description: if the claims cover a range (ratios, intervals, doses) broader than what is supported in the specification, they become vulnerable in post-grant review.
- Claim definiteness and scope creep: method claims that cover broad patient populations or broad indications can be challenged if the specification does not support the breadth.
- Design-around opportunities: if the claim hinges on a particular ratio or timing, a competitor can shift dosing slightly, alter sequence, or use a different formulation to exit the literal claim scope.
What claim categories matter most for freedom to operate (FTO)?
For FTO, the risk usually concentrates on:
- Independent method-of-treatment claims, because any clinical regimen matching the claim’s timing, dose relationship, and indication can create infringement exposure.
- Composition claims, because formulation changes can be the easiest path to a non-infringing design, but if the claim is broad on component selection and composition structure, “simple” changes can fail.
In practice, a competitor’s best defenses are often:
- altering dosing sequence (chronology),
- shifting dose outside claimed ratio ranges,
- changing formulation to avoid the specific physical parameter,
- limiting the indication or patient subgroup (if the claim is indication-bound in a way that affects infringement).
What is the US patent landscape around this invention?
How the landscape typically clusters
For combination therapy and formulation-centric patents like this one, the US landscape usually clusters into four neighboring buckets:
- Foundational single-agent patents for each active component (composition and use).
- Combination patents (fixed-dose combinations, co-administration regimens, and sequences).
- Formulation/process patents (release profile, stability, dosage unit design, and delivery).
- Regulatory-linked patents in the Orange Book (method-of-use and formulation claims tied to approved labeling).
Where overlap tends to occur
Overlap risk tends to concentrate in:
- patents with the same active components, even if the prior art uses different ratio or timing,
- patents claiming the same patient population and therapeutic endpoints,
- formulation patents that produce similar pharmacokinetic or stability outcomes without matching every claimed parameter.
A common outcome in litigation and post-grant proceedings is that:
- art that discloses the actives and indication triggers an obviousness argument,
- the patentee’s differentiation rests on a narrow parameter (ratio, sequence, interval, or release feature) plus supporting data.
Which prior-art types are most likely to challenge US 10,703,816?
What documents are most dangerous in IPR and district court?
In the US, the claims like these are typically attacked using:
- US published applications and issued US patents disclosing the same active combination.
- Guideline-based publications that set standard regimens, if they describe dose relationships and sequencing.
- Clinical trial publications that disclose the treatment schedule and composition components.
- Regulatory submissions and labeling that describe recommended combinations, dose, and administration timing.
Where non-patent literature can still matter
Even if not every article anticipates a claim, non-patent literature is routinely used to:
- establish motivation to combine,
- show routine optimization of dosing and scheduling,
- support expert testimony that the claimed regimen would have been within ordinary skill.
How does the Orange Book track the enforcement leverage?
What to look for (and why it changes bargaining power)
For a formulation and method-of-use patent, the Orange Book record is often where enforcement leverage concentrates because it ties the patent to:
- an approved NDA/BLA,
- a listed drug product,
- and potentially a listed “method of use” claim that can drive ANDA or 505(b)(2) litigation risk.
If the patent is listed for the relevant drug, the landscape becomes more litigation-heavy:
- Paragraph IV challenges can target it,
- ANDA settlement structures can depend on it,
- the patent’s claim set often becomes a focal point for both side arguments.
US claim validity risk map (practical, not theoretical)
What parts of these patents are easiest targets?
In patents of this type, validity risk concentrates on:
- Dose ratio and timing parameters
- If disclosed broadly in the prior art, the claimed “sweet spot” can be argued as routine optimization.
- Indication and patient population limits
- If the specification does not clearly tether the benefit to those limits, claims can be attacked for lack of written description.
- Formulation parameter linkage
- If the specification does not connect the parameter to an advantage with data, obviousness and enablement attacks get traction.
What parts often hold up better
Claims tend to hold up better when they:
- recite a specific formulation and performance parameter tied to measurable outcomes,
- include comparative efficacy data against close alternatives,
- avoid overly broad ranges that go beyond what is supported.
Competitor design-around paths (where the claim likely leaks scope)
How rivals typically avoid infringement
If the patent claims a fixed-dose composition or a fixed regimen, competitors commonly design around by:
- switching from fixed combination to co-administration with a different sequence,
- moving dosing outside the claimed ratio interval,
- changing dosage unit construction to avoid a formulation constraint,
- using a different salt form, excipient package, or release profile that stays outside claim limits.
Design-around effectiveness depends on whether the claim uses:
- a narrow numeric threshold (easier to miss),
- a broad functional result (harder to avoid),
- or both.
Litigation posture: what matters for a fast threat assessment
What you should assume for enforcement strategy
For a US10,703,816-style patent:
- If it includes method-of-use claims tied to labeling, enforcement can target product labeling AND regimen instructions.
- If it includes formulation claims, enforcement can focus on product composition and manufacturing description.
Litigation leverage increases when:
- the patent is Orange Book-listed,
- it has survived prior challenges,
- it covers an essential aspect of the clinical regimen that competitors must follow.
Key Takeaways
- US 10,703,816 claims are best understood as combination therapy and composition/method-of-use constructs that typically differentiate on dosing relationship, administration schedule, and/or formulation parameters.
- Validity pressure in the US most often targets obviousness from known combinations and written description/enablement mismatches around dose ranges or formulation attributes.
- For FTO, the highest exposure points are usually independent method claims and any composition claims that are not easily displaced by minor dose-sequence or formulation shifts.
- The enforcement and litigation landscape is shaped by Orange Book linkage and whether the claims map cleanly to approved labeling or standard-of-care regimens.
- The practical competitive threat depends on whether the claimed differentiator is a narrow parameter with comparative data support or a broad regimen construct that prior art can mimic.
FAQs
1) Is US 10,703,816 mainly a method patent, a composition patent, or both?
It is framed around both composition and method-of-use claims, with composition parameters typically used to support method efficacy.
2) What prior art is usually most relevant to challenge this kind of patent?
US patents and publications that disclose the same active components, plus clinical and guideline literature describing combination dosing and sequencing.
3) What claim element most commonly determines infringement exposure in combination therapy patents?
The dosing relationship and administration timing tied to the claimed regimen, followed by any formulation-specific constraints.
4) What is the fastest route to evaluate FTO risk from this patent?
Map the independent method-of-treatment claims to the exact regimen: active components, dose amounts, ratios, sequencing, and patient population per labeling or protocol.
5) How does Orange Book listing influence enforcement risk?
Orange Book listing increases likelihood of ANDA/505(b)(2) disputes because it ties the patent to regulatory approval and can trigger Paragraph IV litigation.
References
[1] United States Patent and Trademark Office. US Patent 10,703,816. (Patent document).
More… ↓
⤷ Start Trial
|
